High‐grade B‐cell lymphoma developed during the treatment of chronic myeloid leukemia with bosutinib

Tyrosine kinase inhibitor (TKI) can help to increase the survival time in chronic myeloid leukemia (CML) patients; however, the risk of secondary malignancies due to TKIs is a growing concern. Only few reports showed clinical course of patients who developed lymphoma during TKI therapies. Herein, we...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Case Rep
Autors principals: Takakuwa, Teruhito, Sakai, Ryota, Koh, Shiro, Okamura, Hiroshi, Nanno, Satoru, Nakashima, Yasuhiro, Nakane, Takahiko, Koh, Hideo, Hino, Masayuki, Nakamae, Hirohisa
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Case Reports
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7981704/
https://ncbi.nlm.nih.gov/pubmed/33768841
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ccr3.3770
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars